Angiotensin II receptor blockers in pregnancy: A report of five cases

Reproductive Toxicology

Volumn 28, Issue 1, 2009, Pages 109-112

  Gersak, Ksenija ^a   Cvijic, Marta ^a   Cerar, Lilijana Kornhauser ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Angiotensin II receptor blocker; Fetus; Newborn; Oligohydramnios; Pregnancy; Sartans

Indexed keywords

BISOPROLOL; IRBESARTAN; LOSARTAN; LYSINE ACETYLSALICYLATE; METHYLDOPA; METOPROLOL; NIFEDIPINE;

ADULT; AMNION FLUID; ANTIHYPERTENSIVE THERAPY; APNEA; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FETUS MONITORING; GESTATIONAL AGE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; MATERNAL HYPERTENSION; MUSCLE TONE; OLIGOHYDRAMNIOS; PNEUMOTHORAX; POLYDACTYLY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SIDE EFFECT; SMALL FOR DATE INFANT; TERATOGENICITY; TERM BIRTH; UMBILICAL HERNIA;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION; INFANT, NEWBORN; KIDNEY DISEASES; LOSARTAN; OLIGOHYDRAMNIOS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREMATURE BIRTH; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SLOVENIA; TETRAZOLES;

EID: 67349103080     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2009.02.004     Document Type: Article

References (24)

1. Saji H., Yamanaka M., Hagiwara A., and Ijiri R. Losartan and fetal toxic effects [letter]. Lancet 357 9253 (2001) 363
2. Velázquez-Armenta E.Y., Han J.Y., Choi J.S., Yang K.M., and Nava-Ocampo A.A. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 26 (2007) 51-66
3. Bass J.K., and Faix R.G. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. Am J Perinatol 23 (2006) 313-317
4. Serreau R., Luton D., Macher M.A., Delezoide A.L., Garel C., and Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 112 (2005) 710-712
5. Bos-Thompson M.A., Hillaire-Buys D., Muller F., Dechaud H., Mazurier E., Boulot P., et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 39 (2005) 157-161
6. Nayar B., Singhal A., Aggarwal R., and Malhotra N. Losartan induced fetal toxicity. Indian J Pediatr 70 (2003) 923-924
7. Berkane N., Carlier P., Verstraete L., Mathieu E., Heim N., and Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 70 (2004) 547-549
8. Briggs G.G., and Nageotte M.P. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 35 (2001) 859-861
9. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 67 (2003) 591-594
10. http://www.who.int/classifications/icd/en/. [accessed May 10, 2008].
11. Hinsberger A., Wingen A.M., and Hoyer P.F. Angiotensin-II-receptor inhibitors in pregnancy [letter]. Lancet 357 9268 (2001) 1620
12. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (2006) 2443-2451
13. Moore K., and Persaud T.V.N. The developing human: clinically oriented embryology (2008), Saunders, Philadelphia
14. Daïkha-Dahmane F., Levy-Beff E., Jugie M., and Lenclen R. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 21 (2006) 729-732
15. Vendemmia M., Garcia-Méric P., Rizzotti A., Boubred F., Lacroze V., Liprandi A., et al. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists. J Matern Fetal Neonatal Med 18 (2005) 137-140
16. Martinovic J., Benachi A., Laurent N., Daikha-Dahmane F., and Gubler M.C. Fetal toxic effects and angiotensin-II-receptor antagonists [letter]. Lancet 358 9277 (2001) 241-242
17. Pietrement C., Malot L., Santerne B., Roussel B., Motte J., and Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 23 (2003) 254-255
18. Redman C.W., Beilin L.J., Bonnar J., and Ounsted M.K. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 2 7989 (1976) 753-756
19. Smith P., Antony J., and Johanson R. Nifedipine in pregnancy. BJOG 107 3 (2000) 299-307
20. Rumack C.M., Guggenheim M.A., Rumack B.H., Peterson R.G., Johanson M.L., and Braitwaite W.R. Neonatal intracranial haemorrhage and maternal use of aspirin. Obstet Gynecol 58 5 Suppl. (1981) 52S-56S
21. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343 8898 (1994) 619-629
22. Zetterström K., Lindeberg S.N., Haglund B., and Hanson U. The association of maternal chronic hypertension with perinatal death in male and female offspring: a record linkage study of 866,188 women. BJOG 115 (2008) 1436-1442
23. Gilbert W.M., Young A.L., and Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. Reprod Med 52 (2007) 1046-1051
24. Habli M., Levine R.J., Qian C., and Sibai B. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol 197 406 (2007) e1-e7